Do functional changes occur in the bladder due to bladder outlet obstruction? ‐ ICI‐RS 2018

Bosch, J.L.H. Ruud; Abrams, Paul; Averbeck, Márcio Augusto; Agrò, Enrico Finazzi; Gammie, Andrew; Marcelissen, Tom; Solomon, Eskinder

doi:10.1002/nau.24076

Cited by 28 publications

(37 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From the suggestion of the 2018 ICI-RS meeting ( Bosch et al, 2019 ), the process of BOO development included oxidative stress, upregulation of hypoxia-inducible factor (HIF)-1α and vascular endothelial growth factor (VEGF), increased collagen content and detrusor wall thickening. However, in the rat PBOO model, we found hypertrophy of smooth muscle cells and hyperplasia of interstitial cells at week 4 and activation of the adaptive immune response at week 5.…”

Section: Discussionmentioning

confidence: 99%

“…The prevalence of this condition in women has been estimated to be between 2.7 and 29%, and women report fewer classic obstructive symptoms than men ( Patel and Nitti, 2001 ). One of the topical issues from the 2018 International Consultation on Incontinence-Research Society (ICI-RS) meeting shows that functional changes in the bladder occur as a consequence of BOO ( Bosch et al, 2019 ). As Fusco et al (2018) summarized in their review, bladder wall remodeling due to BOO is hypothesized to involve an initial hypertrophy phase, a subsequent compensation phase and a later decompensation phase.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fibroblast Growth Factor 2 Promotes Bladder Hypertrophy Caused by Partial Bladder Outlet Obstruction

Gao

Liu

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Non-invasive biomarkers to identify patients with bladder outlet obstruction (BOO)-related dysfunction are still needed to guide clinical practice. The current study aims to investigate molecular alterations and biomarkers associated with partial BOO (PBOO) in rats. Sprague–Dawley rats were used to establish the BOO model. Serum samples from 60 patients with benign prostatic hyperplasia (BPH) were used for enzyme-linked immunosorbent assay analysis. RNA sequencing and TMT-labeling proteomic analyses were conducted to identify molecular alterations. Masson’s trichrome, H&E, and immunohistochemical staining and western blotting were conducted by using conventional methods following the manufacturer’s instructions. Rats with PBOO experienced hypertrophy of smooth muscle cells and hyperplasia of interstitial cells during the first 4 weeks after the initiation of obstruction. Four weeks later, rats with PBOO showed activation of the adaptive immune response, cell death and apoptosis. The levels of brain-derived neurotrophic factor (BDNF) and fibroblast growth factor 2 (FGF2) in the serum gradually increased in the first 4 weeks and gradually decreased after week 4. FGF2 levels slightly correlated with prostate volume (R = 0.156, P = 0.0028) but not with age or BMI in BPH patients. No correlations were found between BDNF levels and prostate volume, age or BMI. BOO induces a change from bladder compensation to decompensation at week 4. FGF2 is involved in the development of hypertrophy in the PBOO bladder and shows a positive correlation with prostate volume in BPH patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Fibroblast Growth Factor 2 Promotes Bladder Hypertrophy Caused by Partial Bladder Outlet Obstruction

Gao

Liu

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…1996, Dmochowski 2005, Bosch et al . 2019). In our study, it was unclear from the medical records whether dogs suffered from detrusor dysfunction and the rationale for introducing this medication.…”

Section: Discussionmentioning

confidence: 99%

Detrusor urethral dyssynergy in dogs: 35 cases (2007‐2019)

Stilwell¹,

Bazelle

Walker³

et al. 2020

J of Small Animal Practice

View full text Add to dashboard Cite

Objectives To evaluate clinical presentation, diagnosis, treatment and outcome of dogs diagnosed with detrusor urethral dyssynergy. Materials and Methods Multicentre (n = 3 UK referral clinics), retrospective, observational study. Database searches were performed (2007 to 2019) to identify dogs with detrusor urethral dyssynergy. Dogs with structural abnormalities or detectable neurological disorders affecting micturition were excluded. Clinical presentation, diagnostic procedures, treatment and outcome were evaluated. Results Thirty‐five dogs were included. Middle‐aged, large‐breed, male neutered dogs were most frequently documented. Four female dogs were included. Fifteen breeds, including Labrador retrievers (8/35; 22.9%), golden retrievers (5/35;14.3%) and cross‐breeds (5/35; 14.3%) were identified. Median duration of clinical signs was 152 days (range 0 to 1095). All dogs were dysuric at presentation with 17/35 (48.6%) reported to have an altered stream of urine and 17/35 (48.6%) to be stranguric. Follow‐up data were available for 34 dogs (median 136 days, range 4 to 2188). Response was classified as good (20/34; 58.8%), partial (7/34; 20.5%) or poor (7/34; 20.5%). Overall time to response was known for 21 of 34 dogs (partial n = 6, good n = 15) with a median of 11 days (range 1 to 155). Four dogs had surgical intervention (castration n = 4, cystostomy tube n = 2). Three dogs were euthanased due to partial (n = 1) or poor (n = 2) response. Medications were discontinued in 11 of 20 (55.0%) dogs with a good response to therapy, two of these relapsed. Clinical Significance Detrusor urethral dyssynergy is an uncommon micturition disorder in dogs, in particular females. Medical therapy with or without surgery resulted in a favourable prognosis in the majority of dogs, although many require long‐term medication.

show abstract

“…This is a simple, but profoundly startling, observation that may influence understanding of the contractile function of the bladder during voiding after further study. There is increasing appreciation for the role of impaired bladder contractility and its effects on treatment outcomes [20][21][22][23][24]. All of the men with BPH/LUTS in this study exhibited decreased bladder contractility on traditional multichannel urodynamic evaluation (data not shown).…”

Section: Discussionmentioning

confidence: 72%

A pilot study of bladder voiding with real-time MRI and computational fluid dynamics

et al. 2020

View full text Add to dashboard Cite

Lower urinary track symptoms (LUTS) affect many older adults. Multi-channel urodynamic studies provide information about bladder pressure and urinary flow but offer little insight into changes in bladder anatomy and detrusor muscle function. Here we present a novel method for real time MRI during bladder voiding. This was performed in a small cohort of healthy men and men with benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS) to demonstrate proof of principle; The MRI urodynamic protocol was successfully implemented, and bladder wall displacement and urine flow dynamics were calculated. Displacement analysis on healthy controls showed the greatest bladder wall displacement in the dome of the bladder while men with BPH/LUTS exhibited decreased and asymmetric bladder wall motion. Computational fluid dynamics of voiding showed men with BPH/LUTS had larger recirculation regions in the bladder. This study demonstrates the feasibility of performing MRI voiding studies and their potential to provide new insight into lower urinary tract function in health and disease.

show abstract

Do functional changes occur in the bladder due to bladder outlet obstruction? ‐ ICI‐RS 2018

Cited by 28 publications

References 44 publications

Fibroblast Growth Factor 2 Promotes Bladder Hypertrophy Caused by Partial Bladder Outlet Obstruction

Fibroblast Growth Factor 2 Promotes Bladder Hypertrophy Caused by Partial Bladder Outlet Obstruction

Detrusor urethral dyssynergy in dogs: 35 cases (2007‐2019)

A pilot study of bladder voiding with real-time MRI and computational fluid dynamics

Contact Info

Product

Resources

About